pSivida Corp. (PSDV)
-NasdaqGM 5.38 
1.27(30.90%) 4:00PM EDT|After Hours
:
5.33 0.05 (0.93%) 4:27PM EDT - Nasdaq Real Time Price
| Prev Close: | 4.11 |
|---|
| Open: | 4.21 |
|---|
| Bid: | 5.35 x 100 |
|---|
| Ask: | 5.46 x 900 |
|---|
| 1y Target Est: | 5.00 |
|---|
| Beta: | 1.75 |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | 4.20 - 5.41 |
|---|
| 52wk Range: | 1.17 - 5.41 |
|---|
| Volume: | 2,761,326 |
|---|
| Avg Vol (3m): | 220,928 |
|---|
| Market Cap: | 125.34M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.52 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest percentage increasesAP(Tue 1:22PM EDT)
- pSivida Announces That U.K.’s NICE Recommends ILUVIEN® for Chronic Diabetic Macular Edema in Pseudophakic Eyes; NHS Reimbursement Expected to FollowBusiness Wire(Mon, Sep 30)
- Five FDA Approvals and Reviews at Risk Under a Government Shutdown24/7 Wall St.(Mon, Sep 30)
- PSIVIDA CORP. Files SEC form 10-K, Annual ReportEDGAR Online(Fri, Sep 27)
- pSivida to Present at 4th Annual Conference on Biosimilars & BiobettersBusiness Wire(Fri, Sep 27)
- pSivida Corp.'s CEO Discusses F4Q 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Sep 25)
- pSivida Corp. Discusses Q4 2013 Results (Webcast)at Seeking Alpha(Wed, Sep 25)
- PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, Sep 25)
- pSivida Corp. Reports Fourth Quarter and Fiscal Year 2013 ResultsBusiness Wire(Wed, Sep 25)
- Q4 2013 pSivida Corp. Earnings Release - After Market CloseCCBN(Wed, Sep 25)
- pSivida Corp. Announces Fourth Quarter and Fiscal Year 2013 Financial Results Release Date and Conference Call InformationBusiness Wire(Wed, Sep 18)
- A Closer Look At PSivida's Pipelineat Seeking Alpha(Mon, Sep 16)
- pSivida to Present At Two Investment Conferences in SeptemberBusiness Wire(Wed, Sep 4)
- The Fundamental Danger To Biotech And How pSivida's Model Can Help Address Itat Seeking Alpha(Fri, Aug 30)
- Alimera, pSivida Eye Drug Warrants FDA Approval On Third Tryat TheStreet(Wed, Aug 28)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 44.68 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-14)
: | -0.62 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.15 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
pSivida Corp. develops products to deliver drugs and biologics primarily in the United States and the United Kingdom. The company, through its Durasert and BioSilicon technology platforms, focuses on the treatment of chronic diseases of the back o...
View More